Amyris (AMRSQ) Stock Price

Amyris Price

Delisted·May 7, 2024
0.00USD
Last traded price

Over the last 17 years Amyris grew revenue by 31.7% annually, reaching 269.85 M USD. For Amyris, the net margin of -195.9% is up versus -350.8% a few years ago.

Amyris stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Amyris over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Amyris stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Amyris's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Amyris Stock Price History
DateAmyris Price
Access this data via the Eulerpool API

Amyris Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
173.14 M USD
-123.42 M USD
-331.04 M USD
Jan 1, 2021
341.82 M USD
-177.63 M USD
-270.97 M USD
Jan 1, 2022
269.85 M USD
-592.67 M USD
-528.51 M USD
Jan 1, 2023 (e)
487.90 M USD
-309.82 M USD
0.00 USD
Jan 1, 2024 (e)
530.30 M USD
-250.19 M USD
0.00 USD
Jan 1, 2025 (e)
697.93 M USD
-116.80 M USD
-102.43 M USD
Jan 1, 2026 (e)
651.39 M USD
-196.55 M USD
0.00 USD
Jan 1, 2027 (e)
799.80 M USD
-68.14 M USD
0.00 USD

Amyris Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 4:07 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e
41.0043.0034.0067.00127.0063.00152.00173.00341.00269.00487.00530.00697.00651.00799.00975.00
-43.844.88-20.9397.0689.55-50.39141.2713.8297.11-21.1181.048.8331.51-6.6022.7322.03
4.8823.26-8.8214.9351.1841.2750.0049.1354.554.094.094.094.094.094.094.09
2.0010.00-3.0010.0065.0026.0076.0085.00186.0011.0019.9121.6728.5026.6232.6739.87
-110.00-95.00-108.00-88.00-55.00-131.00-121.00-123.00-177.00-592.00-309.00-250.00-116.00-196.00-68.00
-268.29-220.93-317.65-131.34-43.31-207.94-79.61-71.10-51.91-220.07-63.45-47.17-16.64-30.11-8.51
-235.002.00-218.00-97.00-201.00-223.00-242.00-331.00-270.00-528.00-102.00
14.63-100.85-11,000.00-55.50107.2210.958.5236.78-18.4395.56
5.005.208.5015.9032.3060.40364.75364.75364.75364.75364.75364.75364.75364.75364.75364.75
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Amyris generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Amyris retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Amyris's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Amyris has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Amyris's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Amyris stock margins

The Amyris margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amyris. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amyris.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
42.30 %
-207.23 %
-350.79 %
Jan 1, 2019
50.06 %
-79.76 %
-159.13 %
Jan 1, 2020
49.28 %
-71.29 %
-191.20 %
Jan 1, 2021
54.61 %
-51.97 %
-79.27 %
Jan 1, 2022
4.14 %
-219.63 %
-195.86 %
Jan 1, 2023 (e)
4.14 %
-63.50 %
0.00 %
Jan 1, 2024 (e)
4.14 %
-47.18 %
0.00 %
Jan 1, 2025 (e)
4.14 %
-16.74 %
-14.68 %

Amyris Stock Revenue, EBIT, Earnings per Share

The Amyris earnings per share therefore indicates how much revenue Amyris has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
1.05 USD
-2.18 USD
-3.69 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.74 USD
-1.62 USD
-1.45 USD
Jan 1, 2023 (e)
1.52 USD
-0.85 USD
0.00 USD
Jan 1, 2024 (e)
1.65 USD
-0.69 USD
0.00 USD
Jan 1, 2025 (e)
2.18 USD
-0.32 USD
-0.32 USD

Amyris business model & stock analysis

Amyris Inc. is a US-based company specializing in the production of sustainable products. It was founded in 2003 and is headquartered in Emeryville, California. The company aims to promote sustainability in daily life and reduce dependence on fossil fuels. Amyris' business model is based on the discovery and development of biological microorganisms capable of converting sugars and other carbohydrates into valuable products such as fuels, chemicals, and flavors. This technology, known as synthetic biology, was first used for the production of artemisinin, which is used against malaria. Over time, Amyris has expanded its portfolio and specialized in the production of sustainable products for the cosmetics, biofuel, food, and chemical industries. Leading products include Biosolve, an environmentally friendly degreasing solution for the industry, Neossance, a plant-based moisturizer for the cosmetics industry, and Biofene, a bio-based fuel. To produce its products, the company has formed partnerships with various organizations around the world. For example, it has partnered with Total, a French oil and gas company, to establish joint ventures for the production of biofuels. Amyris has also expanded its business by developing a platform for synthetic biology that allows other industry players to develop custom organisms for production processes. This new business model has brought the company into new markets such as the medical and energy sectors. In 2020, the COVID-19 pandemic posed challenges for the company as demand for some products declined. In response, Amyris shifted its production to disinfectants to meet the increased demand for these products. Overall, Amyris has become a leading company in sustainable production and is committed to promoting innovations in synthetic biology to have a positive impact on the environment.

Amyris SWOT Analysis

Strengths

Amyris Inc possesses several key strengths that contribute to its competitive advantage in the market:

  • Advanced Bioengineering Technology: Amyris specializes in using its proprietary technology to engineer microbes and produce sustainable ingredients that have a wide range of applications.
  • Diversified Product Portfolio: The company offers a diverse range of products, including specialty chemicals, flavors, fragrances, and cosmetic ingredients, catering to various industries and consumer needs.
  • Strong Intellectual Property: Amyris has a robust portfolio of patents and intellectual property rights, providing a significant barrier to entry for competitors and ensuring the exclusivity of its innovative products.
  • Strategic Partnerships: The company has established partnerships with global industry leaders, enabling access to distribution channels, resources, and expertise for scaling its operations.

Weaknesses

Despite its strengths, Amyris Inc also faces certain weaknesses that hinder its growth potential:

  • High Research and Development Costs: The company invests a significant portion of its revenue into research and development activities, which may strain its financial resources in the short term.
  • Dependence on Strategic Partnerships: While beneficial, Amyris relies heavily on strategic partnerships for manufacturing, marketing, and distribution support, exposing it to potential risks associated with those partnerships.
  • Regulatory Compliance: As a provider of sustainable and biologically engineered products, Amyris must adhere to stringent regulatory requirements, which may cause delays and additional costs.

Opportunities

Amyris Inc can leverage the following opportunities to drive its growth and market position:

  • Increasing Demand for Sustainable Products: Growing consumer awareness and demand for environmentally friendly and sustainable alternatives present a significant opportunity for Amyris to expand its customer base.
  • Expansion into New Markets: The company can explore untapped markets and industries, such as pharmaceuticals, nutraceuticals, and agriculture, by utilizing its bioengineering capabilities and diverse product portfolio.
  • Growing Clean Beauty Trend: The rising popularity of clean and natural beauty products provides an avenue for Amyris to capitalize on its cosmetic ingredient offerings and cater to the evolving preferences of consumers.

Threats

Despite the opportunities, Amyris Inc must also be aware of potential threats that could impact its business:

  • Intense Competition: The bioengineering industry is becoming increasingly competitive, with numerous players vying for market share, which could lead to price pressures and potential loss of customers.
  • Technological Advancements: Rapid advancements in bioengineering technology may lead to new competitors emerging with superior products or production methods, potentially disrupting Amyris' market position.
  • Economic Factors: Fluctuations in the global economy, currency exchange rates, and commodity prices can have an adverse impact on Amyris' financial performance and profitability.

Amyris Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Amyris historical P/E ratio, EBIT multiple, and P/S ratio

Amyris annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Amyris shares outstanding

The number of shares of Amyris was 364.75 M in 2025. This indicates how many shares Amyris is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
60.40 M Stocks
Jan 1, 2019
60.40 M Stocks
Jan 1, 2020
60.40 M Stocks
Jan 1, 2021
60.40 M Stocks
Jan 1, 2022
364.75 M Stocks
Jan 1, 2023 (e)
364.75 M Stocks
Jan 1, 2024 (e)
364.75 M Stocks
Jan 1, 2025 (e)
364.75 M Stocks

Amyris stock splits

In Amyris's history, there have been no stock splits.
Price targets and forecasts for Amyris are not yet available.

Amyris Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/7/2024-0.15USD-93.68 MUSD-2024 Q1
3/13/2024-0.29USD-90.02 MUSD-2023 Q4

EESG©

Eulerpool ESG Scorecard© for the Amyris stock

67/100
58
Environment
96
Social
47
Governance
E

Environment

20
Scope 1 - Direct Emissions1,520.46
Scope 2 - Indirect emissions from purchased energy1,987.73
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions3,508.19
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees57.85
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Amyris shareholder structure

% Name
27.20335%
Foris Ventures, L.L.C.
Foris Ventures, L.L.C.
1.03907%
Perrara Ventures, LLC
Perrara Ventures, LLC
0.07881%
Kleiner, Perkins, Caufield & Byers
Kleiner, Perkins, Caufield & Byers
0.01754%
Doerr (L John)
Doerr (L John)
0.00443%
Raymond James & Associates, Inc.
Raymond James & Associates, Inc.
0.00343%
FCA Corp.
FCA Corp.
...

Amyris Executives and Management Board

15 members · avg. age 61 · 33 % women

HK

Mr. Han Kieftenbeld (58)

Interim Chief Executive Officer, Chief Financial Officer, Chief Administrative Officer

1.08 M USD

Management

ED

Ms. Elizabeth Dreyer (60)

Chief Accounting Officer, Corporate Controller

DC

Ms. Doris Choi (44)

General Counsel, Secretary

PG

Mr. Philip Gund

Chief Restructuring Officer

Board of Directors

AD

Ms. Ana Dutra (58)

Independent Director

366,050.00 USD
JD

Mr. John Doerr (71)

Independent Director

263,219.00 USD
SM

Mr. Steven Mills (67)

Independent Director · since 2012

262,724.00 USD
JM

Mr. James Mccann (72)

Independent Director

256,110.00 USD
FK

Dr. Frank Kung (74)

Independent Director

253,600.00 USD
RP

Mr. Ryan Panchadsaram (38)

Independent Director

252,998.00 USD

Frequently asked questions about Amyris

Amyris Inc is a leading biotechnology company focused on sustainable ingredients for various industries. Their business model revolves around the production and commercialization of high-performance sustainable products. With a strong emphasis on innovation, Amyris utilizes its proprietary synthetic biology platform to engineer microbes and produce sustainable alternatives to petroleum-derived chemicals. These include renewable ingredients for cosmetics, fragrances, flavors, and nutraceuticals, as well as renewable feedstocks for the production of renewable diesel and jet fuels. By enabling the transition to a more sustainable economy, Amyris Inc aims to deliver environmental benefits while providing quality products to its customers.

Amyris Inc is primarily active in the renewable chemicals and sustainable fuels industries.

The main competitors of Amyris Inc in the market are Evolva Holding SA, Synthetic Genomics Inc, and Intrexon Corporation.

Amyris Inc. is a leading biotechnology company known for its sustainable solutions in the fields of health and wellness, clean beauty, and renewable chemicals. Founded in 2003, Amyris has a rich history marked by its commitment to advancements in synthetic biology. The company's groundbreaking research has enabled the production of a wide range of innovative products, including sustainable ingredients, fragrances, and high-performance materials. Amyris has collaborated with numerous partners and has expanded its global presence, ensuring the adoption of its renewable solutions worldwide. With a strong focus on environmental and societal well-being, Amyris Inc. continues to revolutionize industries through sustainable, nature-inspired innovations.

Amyris Inc has achieved several significant milestones in its trajectory. Notably, the company successfully developed and commercialized its proprietary yeast strain technology, enabling the production of high-value molecules more sustainably. Amyris Inc also established strategic partnerships with various global leaders, expanding its product portfolio and market reach. Additionally, the company made remarkable progress in the renewable energy sector, delivering renewable diesel and jet fuel solutions. Amyris Inc's commitment to sustainability and innovation has garnered accolades, including recognition as a Fast Company Most Innovative Company and a World Economic Forum Technology Pioneer. The company's continuous growth and advancements solidify its position as an industry leader in sustainable solutions.

Amyris Inc is primarily present in countries and regions across the globe, including the United States, Brazil, Europe, and Asia.

Amyris Inc represents a set of core values and corporate philosophy that drive its business operations. The company is committed to delivering sustainable solutions through its advanced biotechnology platform. Amyris focuses on providing renewable products across various industries, including clean beauty, flavors, fragrances, and sweeteners. With an emphasis on innovation, Amyris strives to create high-performance products, enhancing the quality of life while minimizing the environmental impact. The company's dedication to scientific excellence, integrity, and social responsibility enables Amyris to fulfill its mission of positively transforming the world. Amyris Inc consistently pursues its goal of sustainable development and improving global resource efficiency through innovative biotechnology solutions.

8 analysts currently rate the Amyris stock: 0 recommend buying, 3 holding and 5 selling.

Converted at the current exchange rate, the Amyris share trades at 0.00 EUR (0.00 USD).

The Amyris share (AMRSQ) is listed on 5 stock exchanges, including: NASDAQ (AMRS), Frankfurt (3A01.F), München (3A01.MU), Düsseldorf (3A01.DU), SIX (Zürich) (3A01.SW).

Amyris Inc. is an American biotechnology company based in Emeryville, California. Founded in 2003, the company specializes in the development and production of molecules that can serve as the basis for a variety of products, particularly in the cosmetics, skincare, body and hair care, perfume, and fragrance industries. Amyris Inc.'s business model is based on the use of innovative biotechnology platforms for the construction and optimization of microorganisms capable of producing specific molecules, such as essential oils, fats and waxes, sugars, flavors, and other compounds, from sustainable raw materials. The company's focus is on producing molecules from renewable resources such as sugarcane, corn, cellulose, and other bio-based materials. The molecules produced by Amyris are used either directly as end products or as ingredients in other products. Amyris has several divisions, including "Ingredients," "Cosmetics & Personal Care," "Fragrances & Flavors," and "Sweeteners & Nutraceuticals." In the "Ingredients" division, the company produces a variety of molecules that can be used as starting materials for the production of cosmetics and personal care products, cleaning agents, lubricants, and other products. Examples of products include squalene, hyaluronic acid, vitamin E, ferulic acid, caprylic/capric triglycerides, and others. In the "Cosmetics & Personal Care" division, Amyris also offers its own skincare, body, and hair care products based on sustainable, organic ingredients. These include nourishing facial oils, moisturizers, cleansers, shampoos, conditioners, and others. In the "Fragrances & Flavors" division, Amyris produces essential oils, flavors, and fragrances that are used in a variety of applications, including perfumes, room fragrances, scented candles, and aromatherapy products. Key products include lavender oil, cinnamon bark oil, lemon oil, vanillin, and others. Finally, Amyris also offers products in the "Sweeteners & Nutraceuticals" category, including plant-based sweeteners such as rebaudioside A and others, as well as dietary supplements based on omega-3 fatty acids, vitamin D3, and other ingredients. Amyris Inc.'s business model is based on the use of innovative biotechnology platforms for the development and production of molecules that can be used as raw materials for a variety of products. By using sustainable raw materials and producing molecules in an environmentally friendly way, the company has established itself as a pioneer in sustainable chemistry. With a wide range of products and a strong presence in global markets, Amyris Inc. is well positioned to continue growing in the coming years and promote awareness of sustainable innovations in the chemical industry.

The revenue cannot currently be calculated for Amyris.

The profit cannot currently be calculated for Amyris.

The P/E ratio cannot be calculated for Amyris at the moment.

The P/S cannot be calculated for Amyris currently.

The Eulerpool Quality Score for Amyris is 4/10.

The ISIN of Amyris is US03236M2008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Amyris is A2DS41. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Amyris is AMRSQ. The ticker symbol is used to trade Amyris shares on the stock exchange.

Amyris paid dividends every year for the past 0 years.

Amyris is assigned to the 'Commodities' sector.

The dividends of Amyris are distributed in USD.

All fundamentals and in-depth analysis of Amyris

Our stock analysis for Amyris stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amyris. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.